항인 IgE 가토혈청에 의한 피부 및 비점막반응에 관한 연구

Abstract

[한글]

[영문]

It has been subject of controversy for a long time which immunoglobulin the reagin, an antibody for atopic allergy such as nasal allergy and bronchial asthma, should belong to. The immunoglobulin A, IgA, had been a contender until 1966, when Ishizaka proposed that the reagin belonged to a new immunoglobuin E, IgE. As the author obtained anti-human immunoglobulin E rabbit serum at our laboratory in the fall of 1969, IgE and anti-IgE reaction in the skin and mucous membrane has been studied clinically with the serum mainly in the patients with nasal allergy. The study has been carried out by observing the intensity of erythema and wheal reaction following intradermal injections of anti-IgE, eosinophilia induced by anti-IgE, and manifestations of nasal allergy after making contact of the anti-IgE on the surface of the nasal mucous membrane. This study has confirmed clinically that the IgE is the immunoglobulin that belongs to the antibodies which induces nasal allergy in man, and the results can be applied for the diagnosis and evaluation which induces nasal allergy in man, and the results can be applied for

the diagnosis and evaluation of the therapeutic results in patients with nasal allergy. This paper also includes a study on the eosinophil trophic factor in the patients with nasal allergy and in the normal subjects.

In these studies, the following results have been obtained.

1) The atopic and non-atopic could not be differentiated by minimum effective doses contrary to the auther's initial intention. The anti-IgE serum intradermal reaction has produced on erythema-wheal reaction which is the characteristic of atopic allergy, and the size of the reaction has been intensified by

hyposensitization during the first month, and has decreased thereafter.

2) The eosinophilia has been studied by application of anti-IgE serum using thye skin window technique. An increased of eosinophils has been observed in 100 per cent of cases in which nondiluted serum has been used, while it has been observed in 50 per cent of cases in which 1:10 dilution was used. However, there has been no significant difference among the atopic, non-atopic, and normal subjects, and the result was of little help for the diagnosis of the non-allergic. However, the higher the concentration of anti-IgE, the greater was the eosinophilia. The

eosinophilia reached its maximum between 1∼3 hours, and was not influenced by antihistamine preparations. Besides, it has been clarified that eosinophilia is closely related in the allergic reactions in which the IgE is involved.

3) Allergic symptoms were produced by applying the anti-IgE serum to the nasal mucous membrane, but such phenomena were not produced when anti-IgG serum was used. These have been characteristically seen in atopic nasal allergy and have not been

in the normal subjects. It has been found that the intensity of the reaction was decreased by special hyposensitization. Moreover, even in group Ⅲ which has been known as the non-atopic and in the cases in which atopy was suspected and only skin

reaction was positive, the reaction of the nasal mucous membrane by anti-IgE serum has been positive. It has been clarified that the cases with symptoms of nasal allergy can be differentiated by this reaction into the atopic and non-atopic, and the reaction is helpful for the objective evaluation by the hyposensitization.

Besides, it has been clarified that the IgE rather than the IgG is involved int the nasal allergy.